Shuwen Signs Companion Diagnostic Deal with Hengrui Medicine

Shuwen Biotech, a Hangzhou diagnostic company focusing on cancer tests, will collaborate with Jiangsu Hengrui Medicine to develop a companion diagnostic for an unspecified Hengrui cancer treatment. Shuwen will screen clinical trial candidates for the drug at its lab, using the diagnostic, and it will manufacture the product, once Hengrui's cancer drug is approved for use. More details.... Stock Symbol: (SHA: 600276) Share this with colleagues: // //